Literature DB >> 11207302

Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination.

M Zöller1, O Christ.   

Abstract

Clinical success in tumor vaccination frequently does not reach expectation. Since vaccination protocols are quite variable, we used the murine renal cell carcinoma line RENCA transfected with the lacZ gene (RENCA-beta-gal) to compare the efficacy of two different vaccination strategies or their combination and to elaborate on the underlying mechanisms. BALB/c mice were vaccinated either with naked lacZ DNA or with attenuated Salmonella typhimurium transformed with lacZ DNA or with dendritic cells (DC) loaded with the beta-galactosidase protein or mice were vaccinated with both DNA and protein. Although all regimens led to a prolongation of survival time, oral vaccination with transfected S. typhimurium followed by i.v. transfer of protein-loaded DC provided the optimal schedule. In this setting, >50% of mice remained tumor free after challenge with 10 times the lethal tumor dose of RENCA-beta-gal. As explored in transfer experiments, the superior efficacy of combining DNA and protein vaccination is due to the facts that 1) optimal protection depends on both activated CD4(+) and CD8(+) cells and 2) CD8(+) CTL are most strongly activated by vaccination with transformed Salmonella, whereas vaccination with protein-loaded DC is superior for the activation of Th. The latter induced sustained activation of CTL and recruitment of nonadaptive defense mechanisms. The data demonstrate the strength of DNA vaccination, particularly by the oral route, and provide evidence that a combined treatment with protein-loaded DC can significantly increase the therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207302     DOI: 10.4049/jimmunol.166.5.3440

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen.

Authors:  Venkataswarup Tiriveedhi; Nayan J Sarma; Vijay Subramanian; Timothy P Fleming; William E Gillanders; Thallachallour Mohanakumar
Journal:  Hum Immunol       Date:  2011-10-23       Impact factor: 2.850

2.  [Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].

Authors:  A Haferkamp; M Hohenfellner; R Hautmann; M Zöller
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  T/Tn immunotherapy avoiding immune deviation.

Authors:  Hye-Youn Son; Vasso Apostolopoulos; Chul-Woo Kim
Journal:  Int J Immunopathol Pharmacol       Date:  2016-10-19       Impact factor: 3.219

5.  MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization.

Authors:  Hye-Youn Son; Hwan-Kyu Jeong; Vasso Apostolopoulos; Chul-Woo Kim
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

6.  Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen.

Authors:  Christian Ginzkey; Sven Eicker; Matthias Marget; Jörg Krause; Stefan Brecht; Manfred Westphal; Heinz-Hermann Hugo; Maximilian Mehdorn; Jörg Steinmann; Wolfgang Hamel
Journal:  Acta Neurochir (Wien)       Date:  2012-11-08       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.